Correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib

Radiology

Volumn 273, Issue 2, 2014, Pages 452-461

  Thian, Yeeliang ^a   Gutzeit, Andreas ^b,c   Koh, Dow Mu ^a   Fisher, Rosalie ^a   Lote, Hazel ^a   Larkin, James ^a   Sohaib, Aslam ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c Institute of Radiology and Nuclear Medicine St Anna Hospital Luzern   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IOHEXOL; SUNITINIB; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CHOI CRITERIA; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VOLUME; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; MIDDLE AGED; RADIOGRAPHY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; CONTRAST MEDIA; FEMALE; HUMANS; INDOLES; IOHEXOL; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84910027404     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14132702     Document Type: Article

References (25)

1. Fisher R, Gore M, Larkin J. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol 2013;23(1):38-45.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-3590.
3. Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 2009;27(19):3225-3234.
4. Sun M, Shariat SF, Cheng C, et al. Prognostic factors and predictive models in renal cell carcinoma: A contemporary review. Eur Urol 2011;60(4):644-661.
5. Jain RK, Lee JJ, Ng C, et al. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol 2012;30(21):2684-2690.
6. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25(13):1753-1759.
7. Sharma MR, Maitland ML, Ratain MJ. RECIST: no longer the sharpest tool in the oncology clinical trials toolbox-point. Cancer Res 2012;72(20):5145-5149; discussion 5150.
8. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25(13):1760-1764.
9. Nishino M, Jagannathan JP, Krajewski KM, et al. Personalized tumor response assessment in the era of molecular medicine: cancer- specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 2012;198(4):737-745.
10. Pasquier E, Carré M, Pourroy B, et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004;3(10):1301-1310.
11. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010;102(5):803-809.
12. Schmidt N, Hess V, Zumbrunn T, Rothermundt C, Bongartz G, Potthast S. Choi response criteria for prediction of survival in patients with metastatic renal cell car-cinoma treated with anti-angiogenic therapies. Eur Radiol 2013;23(3):632-639.
13. Legramanti S, Antonelli A, Ferrari V, et al. Results of targeted therapies for m1 renal cell carcinoma: our experience [in Italian]. Urologia 2012;79(Suppl 19):72-75.
14. Kang HC, Tan KS, Keefe SM, et al. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. AJR Am J Roentgenol 2013;200(1):120-126.
15. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 2010;194(1):157-165.
16. Nathan PD, Vinayan A, Stott D, Juttla J, Goh V. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010;9(1):15-19.
17. Hittinger M, Staehler M, Schramm N, et al. Course of size and density of metastatic renal cell carcinoma lesions in the early follow- up of molecular targeted therapy. Urol Oncol 2012;30(5):695-703.
18. Krajewski KM, Guo M, Van den Abbeele AD, et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 2011;59(5):856-862.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
20. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: Assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010;194(6):1470-1478.
21. Altman DG. Some common problems in medical research. In: Practical statistics for medical research. London, England: Chapman & Hall, 1991; 404.
22. Bae KT. Intravenous contrast medium administration and scan timing at CT: considerations and approaches. Radiology 2010; 256(1):32-61.
23. Paglino C, Imarisio I, Ganini C, et al. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: A single institution retrospective study. Future Oncol 2012;8(12): 1605-1612.
24. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renalcell carcinoma: An expanded-access trial. Lancet Oncol 2009;10(8):757-763.
25. Goh V, Ng QS, Miles K. Computed tomography perfusion imaging for therapeutic assessment: has it come of age as a biomarker in oncology? Invest Radiol 2012;47(1):2-4.